🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients

Recruitingn/aAges 18 Years - 99 YearsAllJona Hattangadi-Gluth
NCT05576103 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

In this proposal, the investigators introduce a novel, translational study to prospectively examine primary brain tumor patients undergoing fractionated radiation therapy to the brain. Quantitative neuroimaging, radiation dose information, and directed neurocognitive testing will be acquired through this study to improve understanding of cognitive changes associated with radiation dosage to non-targeted tissue, and will provide the basis for evidence-based cognitive- sparing brain radiotherapy.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Patients 18 years or older 2. Karnofsky performance status (KPS) ≥70 3. Life expectancy of ≥1 year 4. Primary brain tumor patients who will receive fractionated partial brain RT 5. Able to complete neurocognitive assessments Exclusion Criteria: 1. Inability to undergo MRI with contrast 2. Prior brain RT
💊

What it tests

  • Not listed
📍

Where

1 site
Moores Cancer Center
San Diego, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy